Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSBiotechnology
+$0.02 today
- Market cap
- $165.63M
- Beta
- 0.35
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.79
Volume 0.81M
Average 0.40M
ABOS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Acumen Pharmaceuticals, Inc.NASDAQ: ABOS
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 71.7% from a year ago
Cash & equivalents stood at $51.8M at the end of Q1 FY2026, up 71.7% from a year earlier and down 4.1% from the prior quarter. Over 3 fiscal years it compounded at -25.4% a year.
Context
- Cash & equivalents amounted to 38.8% of total assets at the end of Q1 FY2026, up 24.0 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +71.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 53.99M USD
- Year-over-year change
- +51.5%
- 4-year CAGR
- -18.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 53.99M | +51.5% |
| FY2024 | 2024-12-31 | 35.63M | -46.7% |
| FY2023 | 2023-12-31 | 66.89M | -48.6% |
| FY2022 | 2022-12-31 | 130.1M | +6.5% |
| FY2021 | 2021-12-31 | 122.16M | — |
Cash & Equivalents vs competitors
How ABOS compares with its peers on the latest reported figures
- ABOS's Mar 2026 cash & equivalents of $51.8M is the 4th highest of the 10 companies compared; the peer median is $39.57M.
- Its year-over-year change of +71.7% is the 4th highest of 10, against a peer median of +14.8%.
- Cash & equivalents amounts to 38.8% of total assets for ABOS, versus a peer median of 32.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $76.96M | +102.7% | -24.7% | 32.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $59.96M | +43.5% | +1.9% | 89.8% |
| Mar 2026 | $56.13M | +14.8% | -28.3% | 95.1% | |
| Mar 2026 | $51.8M | +71.7% | -25.4% | 38.8% | |
| Mar 2026 | $47.32M | -9.8% | -3.9% | 17.4% | |
| Mar 2026 | $39.57M | -11.9% | -8.7% | 13.9% | |
| Mar 2026 | $35M | +89.3% | -74.4% | 18.8% | |
| Mar 2026 | $29.83M | -49.3% | -34.5% | 25.4% | |
| Mar 2026 | $26.27M | -34.2% | -1.5% | 52.8% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $8.13M | +109.1% | -13.7% | 91.3% |
| Peer median (excluding ABOS) | $39.57M | +14.8% | -13.7% | 32.1% | |
Competitors are the stored peer set for ABOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 122.16M | 130.1M | 66.89M | 35.63M | 53.99M |
| Short-term Investments | 72.08M | 47.5M | 176.64M | 135.93M | 62.88M |
| Net Receivables | 0 | 0 | 225K | 0 | 625K |
| Inventory | 0 | 199K | 0 | 159K | 0 |
| Other Current Assets | 2.83M | 1.42M | 1.96M | 5.73M | 4.16M |
| Total Current Assets | 198.66M | 180.33M | 246.62M | 178.31M | 122.25M |
| Property, Plant & Equipment (Net) | 36K | 270K | 503K | 339K | 243K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 169K | 0 | 29K |
| Long-term Investments | 31.62M | 15.84M | 62.55M | 59.97M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 163K |
| Other Non-current Assets | 14K | 151K | 285K | 379K | 146K |
| Total Non-current Assets | 31.67M | 16.26M | 63.51M | 60.69M | 581K |
| Total Assets | 230.33M | 196.59M | 310.13M | 238.99M | 122.83M |
| Account Payables | 1.09M | 1.64M | 1.38M | 5.65M | 554K |
| Short-term Debt | 0 | 0 | 0 | 0 | 8.92M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.96M | 131K | 3.9M | 230K | 4.25M |
| Total Current Liabilities | 5.15M | 7.81M | 12.97M | 27.61M | 30.01M |
| Long-term Debt | 0 | 0 | 27.34M | 29.42M | 22.4M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 2.56M | 0 | 0 |
| Total Non-current Liabilities | 0 | 0 | 30.18M | 29.57M | 22.4M |
| Total Liabilities | 5.15M | 7.81M | 43.15M | 57.18M | 52.4M |
| Common Stock | 4K | 4K | 6K | 6K | 6K |
| Retained Earnings | (127.57M) | (170.43M) | (222.8M) | (325.13M) | (446.46M) |
| Accumulated OCI | (231K) | (751K) | 312K | (48K) | 83K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 225.18M | 188.78M | 266.97M | 181.82M | 70.43M |
| Total Debt | 0 | 105K | 28.49M | 29.7M | 31.31M |
| Net Debt | (122.16M) | (130M) | (38.4M) | (5.93M) | (22.68M) |
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
Intrinsic Alpha fair value
Locked
Current Price
$2.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.